| Conmana (icotinib) / Betta Pharma |
ChiCTR-TRC-14004885: Intercalated combination of chemotherapy and icotinib followed by icotinib maintenance compared with chemotherapy followed by icotinib maintenance in EGFR mutant patients with advanced Non-Small-Cell |
|
|
| Recruiting | 4 | 100 | | Intercalated combination of chemotherapy and icoti ;Chemotherapy followed by icotinib maintenance | The First affiliated Hospital of Guangxi Medical University; The First affiliated Hospital of Guangxi Medical U, Prepare funding by ourselves | NSCLC | | | | |
ChiCTR-OPN-15006795: Bronchial arterial infusion in combination with take icotinib hydrochloride orally for treatment of advanced non-small cell lung cancer |
|
|
| Recruiting | 4 | 40 | | Bronchial arterial infusion in combination with take icotinib hydrochloride orally ;solo bronchial arterial infusion | West China Hospital, Sichuan University; West China Hospital of Sichuan University, self-collected | lung cancer | | | | |
ChiCTR1800018857: Study for Apatinib combined with Icotinib in patients with slow progression of non-small cell lung cancer after failure of Icotinib therapy |
|
|
| Recruiting | 4 | 30 | | Apatinib combined with Icotinib | The First Affiliated Hospital Zhejiang University; None, self-financing | non-small cell lung cance | | | | |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
ChiCTR2300070717: A randomized controlled clinical study to assess the effects of icotinib as adjuvant therapy in patients with EGFR mutation and MRD-positive stage IA2-IB non-small cell lung cancer |
|
|
| Not yet recruiting | 4 | 207 | | Icotinib 125mg, TID, po, continuously used for 2 years ;observation | West China Hospital, Sichuan University; West China Hospital, Sichuan University, self-funded | lung cancer | | | | |
ChiCTR2200061108: A Randomized Controlled Clinical Study to Explore the Clinical Value of MRD Monitoring for Adjuvant Targeted Therapy |
|
|
| Not yet recruiting | 4 | 80 | | Administer icotinib according to MRD status ;Administer icotinib for 3 years | Peking University People’s Hospital; Peking University People’s Hospital, NA | lung cancer | | | | |
CTR20160660: Epitinib versus icotinib in the treatment of EGFR-positive non-small cell lung cancer with brain metastasis |
|
|
| Suspended | 3 | 340 | China | | Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | Non-small cell lung cancer;Oncology | | | | |
ChiCTR-TRC-09000506: A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy |
|
|
| Completed | 3 | 400 | | Icotinib 125mg oral, three times a day; gefitinb dummy, 250mg oral, once a day. ;Gefitinb, 250mg oral, once a day, one tablet; Icotinib dummy, 125mg oral, three times a day | Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Zhejiang Beta Pharma Inc., Zhejiang Beta Pharma Inc. | Non-Small Cell Lung Cancer(NSCLC) | | | | |
ChiCTR-IIR-16007769: Randomized phase III trial of icotinib combined with thoracic radiotherapy vs. icotinib alone in treatment of advanced NSCLC patients with EGFR mutation |
|
|
| Recruiting | 3 | 342 | | icotinib ;icotinib combined with thoracic radiotherapy | Shandong Province Cancer Research Institute; Shandong Province Cancer Research Institute, Icotinib provided by Betta Pharma | NSCLC | | | | |
|
ICTAN, NCT01996098: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation |
|
|
| Recruiting | 3 | 318 | RoW | 6-month Icotinib, BPI-2009, Conmana, 12-month icotinib | Sun Yat-sen University | Lung Cancer | 01/20 | 01/23 | | |
NCT03992885: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. |
|
|
| Recruiting | 3 | 70 | RoW | Icotinib, Pemetrexed, platinum | Tianjin Medical University Cancer Institute and Hospital | Non-squamous Non-small Cell Lung Cancer | 07/20 | 08/25 | | |
| Recruiting | 3 | 601 | RoW | EGFR-TKI, Gefitinib/Tarceva/Icotinib, whole brain radiotherapy, WBRT | Sun Yat-sen University | Non-Small Cell Lung Cancer | 12/21 | 12/22 | | |
SAINT, NCT04797806: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC |
|
|
| Recruiting | 3 | 206 | RoW | Anlotinib, Icotinib | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | 04/22 | 04/23 | | |
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation |
|
|
| Active, not recruiting | 3 | 320 | RoW | Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/22 | 12/23 | | |
SMART, NCT04058704: A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy |
|
|
| Recruiting | 3 | 296 | RoW | Icotinib, SRS/WBRT/HA-WBRT/SMART | Betta Pharmaceuticals Co., Ltd. | Non Small Cell Lung Cancer, Brain Metastases | 12/22 | 12/22 | | |
IPAN study, ChiCTR2100043426: A multicenter, randomized, open-label, phase III clinical trial of Icotinib plus pemetrexed-cisplatin versus pemetrexed-cisplatin as postoperative adjuvant treatment in stage III (N1-N2) non-small cell lung cancer (NSCLC) with EGFR-sensitive mutation |
|
|
| Recruiting | 3 | 155 | | Icotinib Hydrochloride Tablets ;Pemetrexed Disodium for Injection ;Carboplatin Injection ;Cisplatin Injection ;Icotinib Hydrochloride Tablets | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing | Non-small cell lung cancer | | | | |
| Active, not recruiting | 3 | 90 | Europe, Canada, US, RoW | Pimicotinib(ABSK021), Placebo | Abbisko Therapeutics Co, Ltd | Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath | 05/26 | 06/28 | | |
NCT06041776: Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations |
|
|
| Recruiting | 3 | 570 | RoW | Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy | 04/28 | 11/29 | | |
NCT04206072: D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC |
|
|
| Active, not recruiting | 2/3 | 362 | RoW | D-0316 Capsule, Icotinib Hydrochloride Tablets, Conmana | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer, EGFR Gene Mutation | 07/22 | 12/23 | | |
Spring-Lung 6, ChiCTR-IIR-17012197: A phase II, open-label, randomised controlled trial of icotinib with and without metronomic oral vinorelbine as first-line therapy in patients with EGFR mutation-positive advanced nonsquamous non–small-cell lung cancer. |
|
|
| Not yet recruiting | 2 | 120 | | Icotinib 125mg orally(PO) tid + vinorelbine 40mg po three times weekly (Monday-Wednesday-Friday) continuously until disease progression, unacceptable toxicity or patient refusal. ;Icotinib 125mg orally(PO) tid continuously until disease progression, unacceptable toxicity or patient refusal. | Shandong Cancer Hospital and Institute; Shandong Cancer Hospital and Institute, The 13th five-year major new-drug-initiative project | non-small cell lung cancer | | | | |
NCT02726568: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, SRS | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Brain Metastases | 12/21 | 12/22 | | |
GASTO-1031, ChiCTR-IIR-17012741: Phase Il Study of Apatinib Combined with Icotinib Versus Icotinib alone as First-Line Chemotherapy for Patients of Advanced Stage of non squamous NSCLC with EGFR gene mutantion |
|
|
| Not yet recruiting | 2 | 120 | | Take Apatinib (250mg qd, after meals) + Icotinib (125mg, tid, before meals) orally ;Take Icotinib (125mg, tid, before meals) orally | The Affiliated Hospital Guangdong Medical University; Affiliated Hospital Guangdong Medical University, Guangdong Medical University Affiliated Hospital Clinical Research Project | Non-Small Cell Lung Cancer | | | | |
NCT03396185: Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB | 02/22 | 02/23 | | |
NCT03349203: Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/23 | | |
NCT03749213: Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Icotinib, Conmana | Betta Pharmaceuticals Co., Ltd. | EGF-R Positive Non-Small Cell Lung Cancer | 02/22 | 12/24 | | |
NCT02820116: The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 2 | 67 | RoW | Icotinib, Conmana | Beijing Haidian Hospital, Peking University People's Hospital, 307 Hospital of PLA, 309th Hospital of Chinese People's Liberation Army | Non-small Cell Lung Cancer(NSCLC) | 04/23 | 04/23 | | |
NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Recruiting | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT05263947: Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation |
|
|
| Recruiting | 2 | 35 | RoW | Bevacizumab and Icotinib, Combined treatment group | Tianjin Medical University Cancer Institute and Hospital | Carcinoma, Non-Small-Cell Lung, Bevacizumab, EGF-R Positive Non-Small Cell Lung Cancer, Tyrosine Kinase Inhibitor | 10/23 | 12/23 | | |
NCT05007938: Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, Conmana, Befotertinib, D-0316 | Betta Pharmaceuticals Co., Ltd., The First Affiliated Hospital of Xiamen University | Non-Small Cell Lung Cancer | 12/23 | 12/24 | | |
NeoIpower, NCT05104788: A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 27 | RoW | Icotinib, Cisplatin, Carboplatin, Pemetrexed | Beijing Cancer Hospital | Non-Small Cell Lung Cancer | 03/24 | 12/26 | | |
NCT05132985: Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Icotinib, Conmana, Cisplatin, Carboplatin, Pemetrexed | Liaoning Tumor Hospital & Institute | NSCLC, EGF-R Positive Non-Small Cell Lung Cancer | 07/24 | 01/28 | | |
ChiCTR2200060151: Furonertinib mesylate with Icotinib as first line treatment in locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive: a single-arm single-center phase II study |
|
|
| Recruiting | 2 | 40 | | Furmonertinib+Icotinib | Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Xisike-Allist Lung Cancer Target Therapy Research Foundation; Shanghai Allist Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co., Ltd. | Lung cancer | | | | |
NCT05514314: A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection |
|
|
| Not yet recruiting | 2 | 90 | NA | Icotinib | Wu Nan | Non-Small Cell Lung Cancer | 09/24 | 06/25 | | |
| Recruiting | 2 | 128 | RoW | Icotinib, BPI-2009, Conmana | Sun Yat-sen University | Lung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Bronchial Neoplasms, Stage IB Non-small Cell Lung Cancer | 12/25 | 12/25 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
ChiCTR-TNRC-08000194: Phase I/IIA study of Icotinib Hydrochloride Tablets in Various Cancer Patients, mainly in Advanced Non-Small Cell Lung Cancer Patients |
|
|
| Completed | 1/2 | 71 | | Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib(Among them,14 patients were additional ;Oral dosing icotinib tablets, Tid, in continuing 28 days, to assess the safety, tolerance and pharmacokinetics of icotinib. The drug was continued after 28days until documented progressive disease or intolerable toxicity to assess the efficacy of icotinib(Among them,17 patients were additional | The First Affiliated Hospital, College of Medicine, Zhejiang University; Zhejiang Beta Pharma Inc., Zhejiang Beta Pharma Inc. | various cancer patients, mainly in advanced non-small cell lung cancer patients | | | | |
ChiCTR-PPC-15006771: Clinical study of icotinib combined with radiotherapy in the treatment of EGFR mutation in stage III lung adenocarcinoma |
|
|
| Recruiting | 1/2 | 100 | | icotinib ;PP | Department of Radiation Oncology, Chinese PLA General Hospital; Chinese PLA General Hospital, self-financing | Lung cancer | | | | |
ChiCTR2100044216: A patient with advanced non-small cell lung cancer with positive epidermal growth factor receptor (EGFR) gene sensitive mutations and brain metastases was used as a test subject to evaluate the tolerance and efficacy of ametinib combined with icotinib: single arm study |
|
|
| Recruiting | 1/2 | 46 | | Ametinib 55 mg each time (once a day) and icotinib 125 mg each time (3 times a day) ;Ametinib 110 mg each time (1 time a day) and Icotinib 125 mg each time (3 times a day) ;ametinib at a dose of 55 or 110 mg (once a day) and icotinib at a dose of 125 mg (3 times a day) | West China Hospital, Sichuan University; HANSON PHARMA, HANSON PHARMA | Non-small cell lung cancer | | | | |
ChiCTR-ONC-08000113: A phase I study to assess safety, tolerance and pharmacokinetics of oral dosing Icotinib Hydrochloride Tablets |
|
|
| Completed | 1 | 16 | | oral dosing icotinib, bid, in continuing 28 days, to assess safety via collecting blood and urine sample pre-dosing at day1, day11, day18, day25, day31. to assess pharmacokinetics via collecting blood and urine sample pre-dosing at day1, day2, day3, day4, day11, day18, day25, day31 ;oral dosing icotinib, bid, in continuing 28 days, to assess safety via collecting blood and urine sample pre-dosing at day1, day11, day18, day25, day31. To assess pharmacokinetics via collecting blood and urine sample pre-dosing at day1,day2, day3, day4, day11, day18, day25, day31 | Zhejiang Beta Pharma Inc.; Zhejiang Beta Pharma Inc., Zhejiang Beta Pharma Inc. | None small cell lung cancer | | | | |
| Recruiting | 1 | 10 | RoW | Pimicotinib（ABSK021） | Abbisko Therapeutics Co, Ltd | Healthy Subjects | 03/24 | 07/24 | | |
ChiCTR-OOC-14005555: An open-lab, multicenter, prospective study of Icotinib in treating patients with advanced nasopharyngeal carcinoma (NPC) |
|
|
| Not yet recruiting | N/A | 55 | | Icotinib | The First affiliated Hospital of Guangxi Medical University; Level of the institution：, Prepare funding by ourselves | nasopharyngeal carcinoma (NPC) | | | | |
ChiCTR-ONC-14004359: A Single-arm Study to Evaluate the Efficacy of Intercalated Combination of Chemotherapy and Icotinib as First-line Treatment for Patients With Non-Small-Cell Lung Cancer |
|
|
| Recruiting | N/A | 50 | | Chemotherapy (on day 1 of each 3 week cycle) in combination with Icotinib (125mg po TID on days 2-15 of each 3 week cycle) for 4 cycles; then continue to receive Icotinib 125mg po TID daily until progression | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Prepare funding by ourselves | Non-Small-Cell Lung Cancer | | | | |
ChiCTR-INR-16010262: Icotinib concurrent thoracic radiotherapy treat for advanced non-small-cell lung cancer (NSCLC) with an activating EGFR gene mutation |
|
|
| Recruiting | N/A | 90 | | radiotherapy ;icotinib ;icotinib | Shaoxing People's Hospital; Shaoxing People's Hospital, Zhejiang province health department project(2014KYB278) | advanced lung adenocarcinoma | | | | |
ChiCTR-TRC-14004971: Intercalated Combination of Icotinib and Chemotherapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer |
|
|
| Recruiting | N/A | 160 | | Chemotherapy (on day 1 of each 3 week cycle) in combination with Icotinib (125 mg po three times a day on days 2-15 of each 3 week cycle) for 4 cycles; then continue to receive Icotinib 125 mg po three times a day daily until progression ;Receive Icotinib 125 mg po three times a day daily until progression | Shandong University School of Medicine; Qilu Hospital of Shandong University, Conmana Project funds | Non-Small-Cell Lung Cancer | | | | |
ChiCTR2200055244: Phase II clinical study of autologous RAK cells combined with icotinib in the treatment of EGFR-mutated advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 50 | | Autologous RAK cells combined with icotinib | Beijing Hospital; Beijing Hospital, Researcher initiated | non-small cell lung cancer | | | | |
ChiCTR-OOC-17012099: Clinical study of Combined action of Icotinib and brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis |
|
|
| Recruiting | N/A | 60 | | Icotinib and brain radiotherapy | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, CSCO - qilu tumor research fund | lung cancer | | | | |
NCT03983811: Adjuvant Chemotherapy With or Without Intercalated Icotinib |
|
|
| Not yet recruiting | N/A | 174 | NA | Icotinib, Placebo, chemotherapy | Nanfang Hospital of Southern Medical University | Carcinoma, Non-Small-Cell Lung | 10/21 | 10/25 | | |
ChiCTR1900024593: A multicenter, randomized, double-blind, parallel-controlled clinical trial for Anlotinib plus Icotinib versus placebo plus Icotinib in the treatment of stage IIIB-IV EGFR gene-sensitive mutant non-small cell lung cancer patients |
|
|
| Not yet recruiting | N/A | 248 | | Anlotinib plus Icotinib ;placebo plus Icotinib | Guangxi Medical University Affiliated Tumor Hospital; Guangxi Medical University Affiliated Tumor Hospital, CHIA TAI TIANQING (CTTQ) Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
ChiCTR1900025230: A randomized, double-blind, parallel controlled trial for Icotinib double-dose first-line therapy for EGFR 21 exon mutations in advanced non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | 224 | | Icotinib double dose ;Icotinib | Guangxi Medical University Affiliated Tumor Hospital; Guangxi Medical University Affiliated Tumor Hospital, Zhejiang Beida Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
ChiCTR2000036256: A randomized, controlled, double-blind study of Fuzheng Jiedu granules in combination with icotinib in the first-line treatment of EGFR-sensitive mutated advanced lung adenocarcinoma |
|
|
| Not yet recruiting | N/A | 108 | | Fuzheng Jiedu granules and icotinib ;Icotinib | Longhua Hospital, Shanghai University of Traditional Chinese Medicine; Level of the institution：, Shanghai Shenkang Hospital Development Center | Advanced adenocarcinoma lung cancer | | | | |
BELLA, NCT04575415: Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study |
|
|
| Recruiting | N/A | 272 | RoW | Bevacizumab, Avastin, Erlotinib, Tarceva, Gefitinib, Iressa, Icotinib, Conmana, Afatinib, Gilotrif, Dacomitinib, Vizimpro, Osimertinib, Tagrisso | Guangdong Association of Clinical Trials | NSCLC | 05/23 | 12/23 | | |
ChiCTR2100046389: A randomized, double-blind, parallel controlled trial for Icotinib double-dose first-line therapy for EGFR 19 exon mutations in advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 158 | | Icotinib increase ;Conventional dosage of Icotinib | Guangxi Medical University Affiliated Tumor Hospital; Guangxi Medical University Affiliated Tumor Hospital, Betta Pharmaceuticals Co.,Ltd | Non-small cell lung cancer | | | | |
| Recruiting | N/A | 40 | | befotertinib 75mg QD Icotinib 125mg TID | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Betta Pharmaceuticals Co., Ltd. | lung cancer | | | | |
